While thrombopoietin receptor agonists (TPO-RAs), including romiplostim and eltrombopag, have significantly improved ITP management, some patients remain relapsed to multiple lines of therapy, necessitating alternative approaches. The gene discussed is MPL; the disease is autoimmune thrombocytopenic purpura.